| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | Bcl6B |
| Uniprot No | Q8N143 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-480aa |
| 氨基酸序列 | MGSPAAPEGALGYVREFTRHSSDVLGNLNELRLRGILTDVTLLVGGQPLR AHKAVLIACSGFFYSIFRGRAGVGVDVLSLPGGPEARGFAPLLDFMYTSR LRLSPATAPAVLAAATYLQMEHVVQACHRFIQASYEPLGISLRPLEAEPP TPPTAPPPGSPRRSEGHPDPPTESRSCSQGPPSPASPDPKACNWKKYKYI VLNSQASQAGSLVGERSSGQPCPQARLPSGDEASSSSSSSSSSSSEEGPI PGPQSRLSPTAATVQFKCGAPASTPYLLTSQAQDTSGSPSERARPLPGSE FFSCQNSEAVAGCSSGLDSLVPGDEDKPYKCQLCRSSFRYKGNLASHRTV HTGEKPYHCSICGARFNRPANLKTHSRIHSGEKPYKCETCGSRFVQVAHL RAHVLIHTGEKPYPCPTCGTRFRHLQTLKSHVRIHTGEKPYHCDPCGLHF RHKSQLRLHLRQKHGAATNTKVHYHILGGP |
| 预测分子量 | 51,5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于Bcl6B重组蛋白的3篇虚构参考文献示例(基于领域常见研究方向概括)：
---
1. **文献名称**：*Bcl6B Recombinant Protein Regulates Germ Cell Development*
**作者**：Su Y, et al.
**摘要**：研究通过大肠杆菌表达系统纯化Bcl6B重组蛋白，发现其在体外能够抑制生殖细胞凋亡，并通过调控下游靶基因(如Stra8)促进精子发生，揭示了Bcl6B在生殖发育中的关键作用。
---
2. **文献名称**：*Structural Insights into Bcl6B-DNA Interaction by Recombinant Protein Analysis*
**作者**：Liu X, et al.
**摘要**：利用重组Bcl6B蛋白进行X射线晶体学分析，解析了其BTB结构域与DNA结合的分子机制，揭示了特定氨基酸残基在转录抑制功能中的重要性，为靶向药物设计提供结构基础。
---
3. **文献名称**：*Bcl6B Recombinant Protein Suppresses Tumor Growth in Lymphoma Models*
**作者**：Wang H, et al.
**摘要**：体外实验表明，重组Bcl6B蛋白通过竞争性结合癌蛋白Bcl6的启动子区域，抑制淋巴瘤细胞增殖并诱导凋亡，提示其在癌症治疗中的潜在应用价值。
---
(注：以上文献为模拟内容，实际研究中请以真实发表的论文为准。)
Bcl6B (B-cell lymphoma 6B) is a member of the Bcl6 protein family, which functions as transcriptional repressors involved in immune regulation, cell differentiation, and oncogenesis. It shares structural homology with Bcl6. including a conserved N-terminal BTB (Bric-a-brac, Tramtrack, Broad Complex) domain for protein-protein interactions and C-terminal zinc-finger motifs for sequence-specific DNA binding. Bcl6B is predominantly expressed in lymphoid tissues and plays critical roles in germinal center formation, lymphocyte development, and T follicular helper cell differentiation. Its transcriptional repression activity is mediated by recruiting histone deacetylases (HDACs) and other corepressors to modify chromatin structure and suppress target gene expression.
Research highlights its dual role in immune homeostasis and disease. While Bcl6B is essential for normal immune responses, dysregulation contributes to pathologies such as autoimmune disorders and B-cell lymphomas. For instance, aberrant Bcl6B expression disrupts cytokine signaling and promotes lymphomagenesis by silencing tumor suppressor genes. Recombinant Bcl6B protein, typically produced in Escherichia coli or mammalian expression systems, retains functional domains for in vitro studies. It is commonly tagged (e.g., His, GST, or FLAG tags) to facilitate purification and detection in binding assays, chromatin immunoprecipitation, or inhibitor screening.
Researchers utilize recombinant Bcl6B to dissect its molecular mechanisms, identify interacting partners, and develop therapeutic agents targeting its oncogenic activity. Small-molecule inhibitors disrupting Bcl6B-corepressor interactions are under investigation for lymphoma treatment. Additionally, studies using recombinant protein have clarified its role in epigenetic regulation, particularly in balancing pro-inflammatory and anti-inflammatory pathways. Despite overlapping functions with Bcl6. Bcl6B exhibits distinct tissue-specific effects, underscoring the need for isoform-specific research tools like recombinant proteins to advance precision therapeutics.
×
